Multifunctional Lipid Nanoparticles for Protein Kinase N3 shRNA Delivery and Prostate Cancer Therapy
Authors:
- 22 June 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (12) , 4588-4600
Abstract
Protein kinase N3 (PKN3), by virtue of its abnormal expression in prostate cells, has been widely used as a target of RNAi (shRNA, siRNA, miRNA) therapy. The major challenges of PKN3 RNAi therapy lie in how to design effective interference sequences and delivery systems. Herein, new PKN3 shRNA sequences (shPKN3-2459 and shPKN3-3357) were designed, and bioreducible, biodegradable, ionizable lipid-based nanoparticles were developed for shPKN3 delivery. First, an ionizable lipid (DDA-SS-DMA) bridged with disulfide bond and ester bonds was synthesized by a three-step reaction and confirmed by MS, 1H NMR, and 13C NMR. The ionizable lipid was mixed with cholesterol, DSPC, PEG-lipid, and shPKN3 by a microfluidic mixer to prepare lipid nanoparticles (LNP-shPKN3) which were characterized by DLS and TEM. Afterward, the pH and glutathione (GSH)-responsiveness of the DDA-SS-DMA based LNP delivery system were investigated by lysosome escape and gel electrophoresis assays. Compared with the commercial transfection reagent Lipo2000, the DDA-SS-DMA based delivery system showed higher transfection efficiency and lower toxicity. Western blot analysis, invasion tests, and migration assays were performed to evaluate the silencing effect of shPKN3 in vitro. In in vivo studies, high tumor suppression (65.8%) and treatment safety were evident in the LNP-shPKN3-2459 treatment group. Taken together, the DDA-SS-DMA based delivery system encapsulating shPKN3-2459 showed significant antitumor efficacy and might be a promising formulation for the treatment of prostate cancer.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2017ZX09101002-001-004)
This publication has 38 references indexed in Scilit:
- Folate-decorated polymeric Pt( ii ) prodrug micelles for targeted intracellular delivery and cytosolic glutathione-triggered release of platinum anticancer drugsPolymer Chemistry, 2015
- First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2014
- Photodegradable Neutral–Cationic Brush Block Copolymers for Nonviral Gene DeliveryChemistry – An Asian Journal, 2014
- Enhanced Intracellular siRNA Delivery using Bioreducible Lipid‐Like NanoparticlesAdvanced Healthcare Materials, 2014
- Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-carriersTheranostics, 2014
- In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of GlaucomaMolecular Therapy, 2014
- Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA deliveryJournal of Controlled Release, 2010
- Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer ProgressionCancer Research, 2008
- Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant CancerNanomedicine, 2008
- PKN3 is required for malignant prostate cell growth downstream of activated PI 3‐kinaseThe EMBO Journal, 2004